The Role of the Chemokine Receptor CXCR3 Axis in the Efficacy of Oncolytic Vesicular Stomatitis Virus Therapy in Combination with Natural Killer T Cell Activation Immunotherapy in Melanoma

趋化因子受体 CXCR3 轴在溶瘤性水泡性口炎病毒疗法联合自然杀伤 T 细胞激活免疫疗法治疗黑色素瘤的疗效中的作用

• 批准号: 449649
• 负责人: Nickerson Rhea
• 金额: $ 1.27万
• 依托单位: Dalhousie University (Nova Scotia)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-12-01 至 2021-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=449649&lang=en
• 关键词: Cancer Immunotherapy; Chemokines; Cxcl10; Cxcl11; Cxcl9; Cxcr3; Immunology; Melanoma; Natural Killer T Cell Immunotherapy; Oncolytic Virus Therapy; Skin Cancer; Vesicular Stomatitis Virus

One in forty-eight Canadians will develop melanoma in their lifetime, and the last two decades have seen a steady rise in melanoma cases. While surgery is highly effective in early melanoma, advanced melanoma is metastatic and resistant to traditional che

四十八分之一的加拿大人会在一生中患上黑色素瘤，过去二十年来，黑色素瘤病例稳步上升。虽然手术对早期黑色素瘤非常有效，但晚期黑色素瘤是转移性的，对传统的化疗有抵抗力。